What's Going On With Aditxt Stock Wednesday?

Aditxt announced a definitive business combination agreement to separate its subsidiary Ignite Proteomics into an independent public company valued at approximately $150 million. The transaction aims to unlock value and provide Ignite with greater access to growth capital for its precision oncology platform. However, Aditxt shares fell 28.55% in premarket trading Wednesday, trading at $0.02, as the stock remains in a steep downtrend with extremely oversold technical indicators and minimal chart support.